https://www.agencyiq.com/blog/new-bipartisan-legislation-would-create-a-neuroscience-center-of-excellence/ 2022-02-07T13:53:40+00:00 https://www.agencyiq.com/blog/fda-reorganization-adds-structures-to-support-gene-therapy-diagnostics-adpromo-and-more/ 2022-02-07T13:59:44+00:00 https://www.agencyiq.com/blog/fda-publishes-second-round-of-material-safety-reports-for-medical-devices/ 2022-02-07T14:20:23+00:00 https://www.agencyiq.com/blog/wholesale-drug-distribution-regulation-clears-white-house-review/ 2022-02-07T14:25:22+00:00 https://www.agencyiq.com/blog/amid-fda-scrutiny-of-accelerated-approval-sponsors-preemptively-withdraw-products/ 2022-02-07T14:29:58+00:00 https://www.agencyiq.com/blog/fda-reveals-plans-for-several-new-regulations-in-latest-unified-agenda/ 2022-02-07T15:09:05+00:00 https://www.agencyiq.com/blog/the-latest-on-diagnostics-and-omicron/ 2022-02-11T20:19:37+00:00 https://www.agencyiq.com/blog/want-an-investigation-into-data-irregularities-dont-use-the-citizen-petition-process-fda-says/ 2022-02-18T14:26:39+00:00 https://www.agencyiq.com/blog/fda-issues-long-awaited-proposed-medical-device-quality-system-harmonization-rule/ 2022-02-25T16:53:17+00:00 https://www.agencyiq.com/blog/fda-finalizes-guidance-on-inclusion-of-older-adults-in-cancer-trials/ 2022-03-04T17:18:31+00:00 https://www.agencyiq.com/blog/fda-wants-help-with-real-world-data-drug-submission-standards/ 2022-03-11T19:58:26+00:00 https://www.agencyiq.com/blog/the-fda-takes-a-new-look-at-quality-metrics/ 2022-03-11T20:50:42+00:00 https://www.agencyiq.com/blog/fdas-plan-to-study-accelerated-approval/ 2022-03-25T16:39:19+00:00 https://www.agencyiq.com/blog/fda-requests-new-statutory-authority-from-congress-as-part-of-budget-request/ 2022-04-01T14:50:34+00:00 https://www.agencyiq.com/blog/fda-device-cybersecurity-guidance-clears-white-house-review/ 2022-04-08T17:47:18+00:00 https://www.agencyiq.com/blog/fda-provides-updates-to-promotional-materials-submission-guidance/ 2022-04-15T20:54:30+00:00 https://www.agencyiq.com/blog/in-new-goals-letter-fda-and-industry-offer-a-vision-of-the-pdufa-program-through-2027/ 2022-08-26T05:06:45+00:00 https://www.agencyiq.com/blog/behind-schedule-fda-releases-guidance-describing-process-for-obtaining-access-to-generic-drug-samples/ 2022-09-27T21:32:25+00:00 https://www.agencyiq.com/blog/diagnostics-update-the-inaugural-monkeypox-town-hall-and-potential-changes-to-the-covid-19-testing-policy/ 2022-09-27T21:32:56+00:00 https://www.agencyiq.com/blog/monkeypox-eua-declaration-new-guidance-templates-and-the-return-of-the-notification-pathway/ 2022-09-27T21:33:13+00:00 https://www.agencyiq.com/blog/opq-report-continues-the-agencys-quality-maturity-story/ 2022-09-27T21:34:06+00:00 https://www.agencyiq.com/blog/fda-seeks-industry-feedback-on-classification-of-generic-drug-amendments/ 2022-09-27T21:35:36+00:00 https://www.agencyiq.com/blog/the-new-drug-pricing-legislation-what-regulatory-professionals-need-to-know/ 2022-09-27T21:35:56+00:00 https://www.agencyiq.com/blog/cdrh-quietly-continues-research-into-systemic-impacts-of-certain-metals/ 2022-09-27T21:36:14+00:00 https://www.agencyiq.com/blog/senate-bill-proposes-regulatory-overhaul-of-cannabis-and-a-new-fda-center/ 2022-09-27T21:37:09+00:00 https://www.agencyiq.com/blog/fda-concludes-work-on-guidance-on-trial-participation-for-those-with-incurable-cancers/ 2022-09-27T21:37:35+00:00 https://www.agencyiq.com/blog/fda-declines-hearing-request-about-new-dietary-ingredients-enforcement-guidance/ 2022-09-27T21:38:17+00:00 https://www.agencyiq.com/blog/fda-calls-for-omicron-ba-4-5-inclusion-in-bivalent-covid-boosters-for-the-fall/ 2022-09-27T21:38:57+00:00 https://www.agencyiq.com/blog/courtesy-letters-an-fda-communication-type-you-may-not-be-aware-of/ 2022-09-28T13:32:16+00:00 https://www.agencyiq.com/blog/explainer-what-the-updated-21st-century-cures-2-0-draft-would-mean-for-the-life-sciences-industry/ 2022-09-28T15:04:18+00:00 https://www.agencyiq.com/blog/fda-releases-bsufa-iii-commitment-letter-outlining-proposed-changes-to-biosimilar/ 2022-09-28T15:04:52+00:00 https://www.agencyiq.com/blog/fda-issues-initial-draft-guidance-on-leveraging-clinical-and-billing-real-world-data-sources-for/ 2022-09-28T15:05:15+00:00 https://www.agencyiq.com/blog/generic-drug-data-show-steady-year-over-year-trends-in-first-cycle-approvals-refuse-to-receive-decisions/ 2022-09-28T15:05:41+00:00 https://www.agencyiq.com/blog/consequences-of-not-paying-user-fees-discussed-in-2-new-mapps/ 2022-09-28T15:06:04+00:00 https://www.agencyiq.com/blog/fda-publishes-much-anticipated-car-t-guidance/ 2022-09-28T15:06:59+00:00 https://www.agencyiq.com/blog/new-bill-approaches-on-orphan-drug-development/ 2022-09-28T15:07:33+00:00 https://www.agencyiq.com/blog/fda-proposes-updates-to-expanded-access-request-form-to-collect-racial-ethnicity-data/ 2022-09-28T15:07:53+00:00 https://www.agencyiq.com/blog/meeting-preview-fda-adcomm-to-discuss-first-alzheimers-therapy-to-treat-psychosis/ 2022-09-28T15:08:23+00:00 https://www.agencyiq.com/blog/white-house-clears-three-fda-guidances-focused-on-drug-importation-shortages-and-container-labeling/ 2022-09-28T15:08:45+00:00 https://www.agencyiq.com/blog/house-committee-advances-amended-user-fee-package-to-the-full-house-floor/ 2022-09-28T15:09:12+00:00 https://www.agencyiq.com/blog/fda-releases-24-new-14-revised-product-specific-guidances/ 2022-09-28T15:09:36+00:00 https://www.agencyiq.com/blog/diagnostic-update-pre-sub-acceptance-predicting-the-transition-timeline-and-a-new-mou-on-lab-capacity/ 2022-09-28T15:09:58+00:00 https://www.agencyiq.com/blog/cdrh-floats-expansion-of-master-file-sterility-pilot/ 2022-09-28T15:10:19+00:00 https://www.agencyiq.com/blog/update-to-fda-annual-reporting-requirements-for-inds-under-white-house-review/ 2022-09-28T15:10:37+00:00 https://www.agencyiq.com/blog/cber-planning-final-guidance-on-studying-multiple-versions-of-cell-and-gene-therapies/ 2022-09-28T15:11:05+00:00 https://www.agencyiq.com/blog/diagnostics-update-first-combined-covid-monkeypox-town-hall-focuses-on-new-guidance-expectations/ 2022-09-30T15:00:11+00:00 https://www.agencyiq.com/blog/draft-fda-guidance-clarifies-a-new-process-to-boost-competition-speed-generic-drugs-in-emergencies/ 2022-10-06T20:20:24+00:00 https://www.agencyiq.com/blog/a-look-at-what-remains-on-fdas-2022-guidance-agendas/ 2022-10-14T15:36:43+00:00 https://www.agencyiq.com/blog/fda-announces-continuation-of-program-to-support-complex-and-innovative-trial-designs/ 2022-10-21T22:41:58+00:00 https://www.agencyiq.com/blog/creepy-crawly-compliance-the-fdas-recent-warning-letters-for-insects-and-pests/ 2022-10-29T02:08:56+00:00 https://www.agencyiq.com/blog/fda-warns-walmart-amazon-for-logistics-role-in-fulfillment-of-orders-for-suspect-products/ 2022-11-04T21:31:13+00:00 https://www.agencyiq.com/blog/new-fda-guidance-explains-how-the-agency-determines-if-an-active-ingredient-is-the-same-as-another/ 2022-11-11T23:53:39+00:00 https://www.agencyiq.com/blog/in-anticipation-of-potential-naloxone-rx-to-otc-switch-fda-requests-info-on-regulatory-scientific-issues/ 2022-11-22T01:26:27+00:00 https://www.agencyiq.com/blog/legislative-update-as-end-of-year-omnibus-approaches-a-look-at-what-is-on-the-table/ 2022-12-03T00:56:36+00:00 https://www.agencyiq.com/blog/clinical-decision-support-aiml-and-reimbursement-questions-take-center-stage-at-digital-health-law-event/ 2022-12-07T23:12:28+00:00 https://www.agencyiq.com/blog/kyriakides-proposes-immediate-risk-based-mdr-extension-at-epsco-meeting/ 2022-12-09T23:16:25+00:00 https://www.agencyiq.com/blog/four-things-to-watch-on-accelerated-approval-as-we-head-into-2023/ 2022-12-16T22:25:09+00:00 https://www.agencyiq.com/blog/as-we-wait-for-fdas-fall-2022-unified-agenda-a-look-at-what-regulations-are-likely-ahead-for-next-year/ 2022-12-22T21:50:45+00:00 https://www.agencyiq.com/blog/welcome-to-2023-what-you-missed-during-the-holiday-break/ 2023-01-04T17:29:03+00:00 https://www.agencyiq.com/blog/five-key-takeaways-from-fdas-2022-advisory-committee-meetings/ 2023-01-09T14:37:25+00:00 https://www.agencyiq.com/blog/white-house-floats-a-national-clinical-trial-governance-committee-for-future-emergencies/ 2023-01-17T16:16:47+00:00 https://www.agencyiq.com/blog/fda-proposes-guidance-for-dose-optimization-in-oncology-trials/ 2023-01-23T17:06:28+00:00 https://www.agencyiq.com/blog/after-4-year-review-fda-shuts-down-attempt-to-regulate-cbd-as-a-supplement-and-asks-congress-for-help/ 2023-01-27T22:08:51+00:00 https://www.agencyiq.com/blog/cder-unveils-new-guidance-agenda-for-2023-with-42-new-policies-planned/ 2023-02-07T17:45:52+00:00 https://www.agencyiq.com/blog/highlights-from-the-third-otat-town-hall-considerations-for-rare-diseases/ 2023-02-10T23:58:30+00:00 https://www.agencyiq.com/blog/fda-outlines-its-approach-to-new-meeting-types-focused-on-generic-drugs/ 2023-02-22T00:51:32+00:00 https://www.agencyiq.com/blog/fda-announces-patient-focused-drug-development-meeting-on-long-covid/ 2023-03-03T21:19:08+00:00 https://www.agencyiq.com/blog/fda-publishes-discussion-paper-on-ai-in-drug-manufacturing/ 2023-03-13T16:18:19+00:00 https://www.agencyiq.com/blog/growing-interest-in-rna-based-medicines-may-necessitate-a-new-class-of-pharmaceuticals/ 2023-03-17T18:23:48+00:00 https://www.agencyiq.com/blog/fda-finalizes-guidance-on-key-definitions-under-the-drug-supply-chain-security-act/ 2023-03-27T18:26:31+00:00 https://www.agencyiq.com/blog/congress-pushes-for-new-fda-authorities-to-identify-and-address-drug-shortages/ 2023-03-31T17:32:32+00:00 https://www.agencyiq.com/blog/fda-guidance-clarifies-requirements-for-reporting-drug-shortages-building-on-pandemic-era-approach/ 2023-04-14T14:09:52+00:00 https://www.agencyiq.com/blog/fda-releases-long-overdue-guidance-on-content-and-format-of-otc-drug-submissions/ 2023-04-21T16:48:20+00:00 https://www.agencyiq.com/blog/fda-outlines-acute-radiation-syndrome-drug-development-expectations-under-its-animal-rule/ 2023-04-28T20:41:12+00:00 https://www.agencyiq.com/blog/fdas-vaccines-advisory-committee-to-consider-annual-strain-selection-for-covid-19-vaccines/ 2023-05-15T13:57:36+00:00 https://www.agencyiq.com/blog/fda-comes-full-circle-with-new-guidance-on-testing-products-for-toxic-ingredients-deg-and-eg/ 2023-05-19T15:56:19+00:00 https://www.agencyiq.com/blog/seeking-to-accelerate-pediatric-drug-development-fda-offers-guidance-on-requirements-of-two-pivotal-laws/ 2023-05-26T16:08:40+00:00 https://www.agencyiq.com/blog/cdrh-hopes-to-release-the-qmsr-final-rule-later-this-year-heres-why-were-skeptical/ 2023-06-02T15:48:46+00:00 https://www.agencyiq.com/blog/fda-unveils-long-awaited-patient-medication-information-proposed-rule/ 2023-06-09T15:50:27+00:00 https://www.agencyiq.com/blog/fda-set-to-unveil-new-rule-on-laboratory-developed-tests-this-august/ 2023-06-27T16:16:02+00:00 https://www.agencyiq.com/blog/epa-investigation-finds-60m-delta-in-water-grants/ 2023-07-05T17:02:27+00:00 https://www.agencyiq.com/blog/fda-quietly-kicks-off-process-that-could-inform-future-rare-disease-regulatory-reforms/ 2023-07-05T17:02:29+00:00 https://www.agencyiq.com/blog/fda-makes-significant-qualitative-changes-in-its-final-guidance-on-quantitative-information-in-drug-advertising/ 2023-07-07T15:34:50+00:00 https://www.agencyiq.com/blog/congress-prepares-to-markup-pandemic-legislation-all-but-confirming-fda-related-provisions-wont-advance/ 2023-07-21T16:37:25+00:00 https://www.agencyiq.com/blog/the-next-chapter-in-the-ctdna-story-still-promising-not-ready-for-prime-time/ 2023-07-28T14:16:43+00:00 https://www.agencyiq.com/blog/in-new-contract-notices-fda-seeks-help-on-user-fee-commitments-and-moving-opioid-oncology-priorities-forward/ 2023-08-04T16:29:58+00:00 https://www.agencyiq.com/blog/fda-looking-to-beef-up-its-remote-assessments-with-artificial-intelligence/ 2023-08-18T18:05:30+00:00 https://www.agencyiq.com/blog/fdas-informed-consent-guidance-gets-a-21st-century-makeover/ 2023-08-25T16:17:53+00:00 https://www.agencyiq.com/blog/new-fda-guidance-on-interchangeable-biosimilar-labeling-heads-to-white-house-for-review/ 2023-09-01T15:28:03+00:00 https://www.agencyiq.com/blog/how-to-handle-a-warning-letter-fdas-new-meeting-type-benefits-generic-drug-companies/ 2023-09-15T20:15:17+00:00 https://www.agencyiq.com/blog/for-first-time-fda-releases-otc-drug-user-fees-prior-to-start-of-government-fiscal-year/ 2023-09-22T16:47:15+00:00 https://www.agencyiq.com/blog/in-a-first-fda-tackles-treatments-for-stimulant-use-disorder/ 2023-10-13T20:12:43+00:00 https://www.agencyiq.com/blog/leaders-at-fda-share-highlights-and-updates-for-drugs-and-biologics-at-raps-convergence/ 2023-10-20T15:15:31+00:00 https://www.agencyiq.com/blog/fdas-newest-draft-guidance-lays-out-considerations-for-developing-treatments-for-diabetic-foot-infections/ 2023-10-27T16:59:15+00:00 https://www.agencyiq.com/blog/following-a-2018-draft-framework-fda-unveils-long-awaited-pdurs-draft-guidance/ 2023-10-27T17:00:04+00:00 https://www.agencyiq.com/blog/mhra-fda-and-health-canada-offer-guiding-principles-for-predetermined-change-control-plans/ 2023-11-03T15:56:19+00:00 https://www.agencyiq.com/blog/top-questions-on-fdas-proposed-ldt-rule-carve-outs-capacity-and-quality-systems/ 2023-11-10T17:56:39+00:00 https://www.agencyiq.com/blog/the-fda-is-in-dire-need-of-some-regulatory-design-thinking/ 2023-11-10T18:06:15+00:00 https://www.agencyiq.com/blog/the-artificial-intelligence-executive-order-what-does-it-mean-for-fda-and-its-regulated-industries/ 2023-11-20T20:02:17+00:00 https://www.agencyiq.com/blog/advisors-and-fda-agree-reclassify-blood-irradiators-for-malignancy-prevention-to-high-risk/ 2023-11-27T17:44:40+00:00 https://www.agencyiq.com/blog/key-takeaways-from-fdas-contracted-report-on-legacy-medical-device-cybersecurity/ 2023-12-01T17:18:43+00:00 https://www.agencyiq.com/blog/fda-updates-guidance-on-developing-drugs-for-covid-19-replacing-pandemic-era-version/ 2023-12-11T17:20:39+00:00 https://www.agencyiq.com/blog/fda-to-propose-revamps-to-guidance-development-and-communication-process-in-coming-weeks/ 2023-12-11T17:42:20+00:00 https://www.agencyiq.com/blog/fda-offers-a-status-check-on-its-diversity-in-research-provisions-one-year-post-fdora/ 2023-12-15T18:16:39+00:00 https://www.agencyiq.com/blog/agencyiq-centralized-platform-aids-team-workflow/ 2024-01-03T19:22:02+00:00 https://www.agencyiq.com/blog/fda-unveils-details-about-major-proposed-changes-to-organization-including-ora-and-office-of-the-commissioner/ 2024-01-05T17:03:20+00:00 https://www.agencyiq.com/blog/agencyiq-offers-unified-source-for-regulatory-analysis-reports-and-news/ 2024-01-10T19:54:57+00:00 https://www.agencyiq.com/blog/addressing-benzene-contamination-fda-issues-guidance-for-reformulating-products-containing-certain-carbomers/ 2024-01-12T21:43:44+00:00 https://www.agencyiq.com/blog/cders-latest-novel-drug-approvals-report-shows-how-the-pandemic-is-still-affecting-some-drug-approvals/ 2024-01-19T17:27:42+00:00 https://www.agencyiq.com/blog/regulatory-and-legislative-monitoring-simplified-with-agencyiqs-unique-tools/ 2024-01-24T17:59:48+00:00 https://www.agencyiq.com/blog/fda-looks-to-fund-ai-ml-based-postmarket-surveillance-research-approach-for-complex-generics/ 2024-01-26T17:52:30+00:00 https://www.agencyiq.com/blog/fda-proposes-first-update-to-orthopedic-device-coating-guidance-since-1990s/ 2024-02-02T21:55:22+00:00 https://www.agencyiq.com/blog/diagnostics-landscape-analysis-key-issues-and-a-look-ahead-at-2024/ 2024-02-12T17:02:05+00:00 https://www.agencyiq.com/blog/new-regulatory-playbook-from-fda-supported-bespoke-gene-therapy-consortium-aims-to-accelerate-development/ 2024-02-16T21:00:42+00:00 https://www.agencyiq.com/blog/what-weve-heard-at-cdrhs-recent-medical-device-sterilization-town-halls/ 2024-02-23T18:15:16+00:00 https://www.agencyiq.com/blog/revised-guidance-on-covid-19-symptom-assessment-incorporates-new-knowledge-adds-flexibility/ 2024-03-01T16:28:00+00:00 https://www.agencyiq.com/blog/explainer-what-a-government-shutdown-would-mean-for-the-fda-updated/ 2024-03-07T21:16:44+00:00 https://www.agencyiq.com/blog/vaccines-advisory-panel-endorses-move-to-trivalent-formulation-for-u-s-flu-vaccines/ 2024-03-15T17:05:31+00:00 https://www.agencyiq.com/blog/fda-drafts-select-updates-to-guidance-on-medical-device-cybersecurity-addressing-statutory-requirements/ 2024-03-25T19:00:59+00:00 https://www.agencyiq.com/blog/in-proposed-rule-fda-offers-up-a-surprisingly-sparse-list-of-drugs-that-present-demonstrable-compounding-difficulties/ 2024-03-29T18:23:05+00:00 https://www.agencyiq.com/blog/fdas-oncology-advisory-committee-to-consider-mrd-as-a-multiple-myeloma-endpoint/ 2024-04-08T18:59:18+00:00 https://www.agencyiq.com/blog/what-we-expect-european-regulators-to-do-in-april-2024/ 2024-04-09T16:01:10+00:00 https://www.agencyiq.com/blog/agencyiq-guidance-tracker-european-medical-device-and-diagnostics-guidance-documents/ 2024-04-09T16:01:24+00:00 https://www.agencyiq.com/blog/core-md-research-showcases-possibilities-of-patient-reported-outcomes-in-high-risk-device-clinical-investigations/ 2024-04-09T16:01:39+00:00 https://www.agencyiq.com/blog/british-regulators-tease-new-device-regulations-in-informative-live-session/ 2024-04-09T16:01:57+00:00 https://www.agencyiq.com/blog/overdue-ema-reflection-paper-on-drug-dosing-in-obesity-introduces-more-questions-than-answers/ 2024-04-09T16:02:20+00:00 https://www.agencyiq.com/blog/mhra-selects-eight-technologies-to-help-it-test-its-new-innovative-devices-pathway/ 2024-04-09T16:02:33+00:00 https://www.agencyiq.com/blog/fda-and-ema-re-launch-parallel-advice-pilot-for-complex-generics/ 2024-04-09T16:02:44+00:00 https://www.agencyiq.com/blog/ema-finalizes-clinical-anticancer-therapeutic-guidance-update/ 2024-04-09T16:02:56+00:00 https://www.agencyiq.com/blog/proposal-for-ivdr-extension-also-impacts-mdr-eudamed/ 2024-04-09T16:03:09+00:00 https://www.agencyiq.com/blog/emas-2023-new-medicines-report-suggests-return-to-pre-pandemic-volume/ 2024-04-09T16:05:07+00:00 https://www.agencyiq.com/blog/new-roadmap-sets-out-u-k-device-regulation-timelines/ 2024-04-09T16:05:22+00:00 https://www.agencyiq.com/blog/swissmedic-reorg-adds-new-focus-on-medical-device-market-surveillance/ 2024-04-09T16:05:37+00:00 https://www.agencyiq.com/blog/ema-publishes-union-list-of-critical-medicines/ 2024-04-09T16:05:50+00:00 https://www.agencyiq.com/blog/commission-designates-first-e-u-reference-laboratories-for-class-d-ivds/ 2024-04-09T16:06:02+00:00 https://www.agencyiq.com/blog/what-we-expect-european-regulators-to-do-in-december-2023/ 2024-04-09T16:06:13+00:00 https://www.agencyiq.com/blog/with-all-nitrosamines-deadlines-passed-ema-updates-its-guidelines/ 2024-04-09T16:06:25+00:00 https://www.agencyiq.com/blog/ema-publishes-first-electronic-product-information-as-pilot-progresses/ 2024-04-09T16:06:38+00:00 https://www.agencyiq.com/blog/what-you-need-to-know-about-the-status-of-the-proposed-ema-fees-regulation/ 2024-04-09T16:07:04+00:00 https://www.agencyiq.com/blog/european-commission-reveals-action-plan-to-address-medicines-shortages/ 2024-04-09T16:07:37+00:00 https://www.agencyiq.com/blog/what-we-expect-european-regulators-to-do-in-november-2023/ 2024-04-09T16:07:49+00:00 https://www.agencyiq.com/blog/what-europes-proposed-data-act-means-for-device-manufacturers-a-deep-dive/ 2024-04-09T16:08:01+00:00 https://www.agencyiq.com/blog/mhra-introduces-an-expanded-international-recognition-procedure-while-planning-to-sunset-the-current-ec-reliance-pathway/ 2024-04-09T16:08:12+00:00 https://www.agencyiq.com/blog/new-mhra-windsor-framework-documents-guide-post-brexit-flow-of-medicines-for-u-k-great-britain-and-the-e-u/ 2024-04-09T16:08:23+00:00 https://www.agencyiq.com/blog/ema-provides-mid-point-progress-report-on-real-world-evidence-development-strategies/ 2024-04-09T16:08:34+00:00 https://www.agencyiq.com/blog/what-will-the-orphan-drug-market-exclusivity-haircut-mean-for-industry/ 2024-04-09T16:08:46+00:00 https://www.agencyiq.com/blog/ema-concept-paper-offers-litany-of-concerns-for-use-of-single-arm-trials/ 2024-04-09T16:08:57+00:00 https://www.agencyiq.com/blog/darwin-eu-completed-the-first-studies-and-needs-new-data-partners/ 2024-04-09T16:09:08+00:00 https://www.agencyiq.com/blog/fda-flexes-its-new-accelerated-approval-authorities-hoping-to-accelerate-access-to-confirmatory-data/ 2024-04-12T14:58:57+00:00 https://www.agencyiq.com/blog/ema-extends-scientific-advice-pilot-for-high-risk-medical-devices/ 2024-04-12T18:05:56+00:00 https://www.agencyiq.com/blog/fda-updates-set-the-stage-for-broader-use-of-harmonized-standards-for-safety-reporting/ 2024-04-12T18:05:58+00:00 https://www.agencyiq.com/blog/beyond-bridging-how-the-fda-is-changing-the-way-it-looks-at-foreign-clinical-data-and-diversity/ 2024-04-19T14:21:48+00:00 https://www.agencyiq.com/blog/draft-guidance-on-potency-assays-for-cgt-products-garners-extensive-stakeholder-input/ 2024-04-19T16:35:27+00:00 https://www.agencyiq.com/blog/the-vote-is-in-the-european-parliament-has-adopted-the-compromise-pharmaceutical-legislation/ 2024-04-19T16:35:29+00:00 https://www.agencyiq.com/blog/accelerated-removal-fda-making-use-of-new-authority-to-withdraw-ineffective-drugs-more-quickly/ 2024-04-19T18:04:35+00:00 https://www.agencyiq.com/blog/how-a-failed-als-drug-provides-a-blueprint-for-the-fda-to-create-a-conditional-withdrawal-pathway/ 2024-04-22T16:47:43+00:00 https://www.agencyiq.com/blog/fda-advisors-endorse-minimal-residual-disease-mrd-as-accelerated-approval-endpoint-for-multiple-myeloma/ 2024-04-26T17:52:15+00:00 https://www.agencyiq.com/blog/draft-guideline-modernizes-ema-recommendations-on-quality-of-inhaled-nasal-products/ 2024-04-26T17:52:16+00:00 https://www.agencyiq.com/blog/to-combat-antimicrobial-resistance-the-fda-needs-a-reset/ 2024-04-30T15:21:04+00:00 https://www.agencyiq.com/blog/the-european-commission-launches-a-new-critical-medicines-alliance/ 2024-05-03T16:29:45+00:00 https://www.agencyiq.com/blog/fdas-fast-moving-ldt-rule-obtains-white-house-clearance-paving-the-way-for-publication/ 2024-05-03T16:29:47+00:00 https://www.agencyiq.com/blog/how-the-fdas-new-ldt-regulation-could-affect-drug-development/ 2024-05-07T16:03:14+00:00 https://www.agencyiq.com/blog/with-the-new-ldt-final-rule-fda-works-to-clarify-what-emergency-response-will-look-like-going-forward/ 2024-05-10T17:04:33+00:00 https://www.agencyiq.com/blog/what-we-expect-european-regulators-to-do-in-may-2024/ 2024-05-10T17:04:35+00:00 https://www.agencyiq.com/blog/how-fdas-laboratory-developed-test-rule-could-delay-some-drug-approvals/ 2024-05-14T15:08:43+00:00 https://www.agencyiq.com/blog/fda-holds-the-line-on-remanufacturing-definitions-in-newly-finalized-guidance/ 2024-05-17T20:39:13+00:00 https://www.agencyiq.com/blog/european-ombudsman-suggests-commission-needs-more-robust-evidence-when-reclassifying-medical-devices/ 2024-05-17T20:39:16+00:00 https://www.agencyiq.com/blog/house-legislators-set-to-markup-legislation-related-to-rare-diseases-pediatric-oncology-and-hct-ps/ 2024-05-28T16:30:05+00:00 https://www.agencyiq.com/blog/new-fda-guidance-on-addressing-misinformation-under-white-house-review/ 2024-05-31T18:39:15+00:00 https://www.agencyiq.com/blog/u-k-regulator-lays-out-proposal-for-international-device-and-diagnostics-recognition/ 2024-05-31T18:39:19+00:00 https://www.agencyiq.com/blog/the-fda-wants-to-kill-the-interchangeable-biosimilar-its-not-waiting-on-congress-to-start-the-burial-preparations/ 2024-06-05T15:37:21+00:00 https://www.agencyiq.com/blog/surrogate-endpoints-why-they-sometimes-succeed-and-sometimes-fail-and-what-that-means-for-patients/ 2024-06-05T19:30:25+00:00 https://www.agencyiq.com/blog/has-the-fda-lost-the-plot-on-surrogate-endpoints/ 2024-06-05T19:30:33+00:00 https://www.agencyiq.com/blog/adcomm-votes-in-favor-of-new-colorectal-cancer-screening-test-but-questions-about-serial-testing-and-labeling-remain/ 2024-06-07T16:48:00+00:00 https://www.agencyiq.com/blog/fdas-new-guidance-explains-what-to-do-during-a-bimo-inspection/ 2024-06-17T17:41:11+00:00 https://www.agencyiq.com/blog/the-devil-is-in-the-details-a-deep-dive-into-the-state-of-notified-body-designations/ 2024-06-17T17:41:12+00:00 https://www.agencyiq.com/blog/fda-further-blurs-the-line-between-biosimilars-and-interchangeables/ 2024-06-21T20:15:26+00:00 https://www.agencyiq.com/blog/in-unanimous-decision-supreme-court-solves-fdas-standing-issue/ 2024-06-21T21:00:24+00:00 https://www.agencyiq.com/blog/new-mdr-ivdr-standardization-request-adds-standards-moves-deadlines/ 2024-06-21T21:00:25+00:00 https://www.agencyiq.com/blog/what-we-heard-at-fdas-listening-session-on-advisory-committee-processes-the-agencys-priorities-vary-wildly-from-the-publics/ 2024-06-24T19:14:58+00:00 https://www.agencyiq.com/blog/icmra-gives-early-readout-on-collaborative-assessment-hybrid-inspection-pilots/ 2024-06-27T19:16:24+00:00 https://www.agencyiq.com/blog/fda-finalizes-guidance-extending-inspection-authority-to-medical-devices/ 2024-06-28T16:49:52+00:00 https://www.agencyiq.com/blog/commission-proposes-guidelines-to-flesh-out-the-newly-finalized-variations-regulation/ 2024-06-28T16:49:54+00:00 https://www.agencyiq.com/blog/in-the-aftermath-of-the-repeal-of-chevron-fda-faces-a-congressional-brain-drain/ 2024-07-08T17:09:57+00:00 https://www.agencyiq.com/blog/fda-draft-guidance-on-addressing-misinformation-clears-white-house-review/ 2024-07-08T18:17:57+00:00 https://www.agencyiq.com/blog/new-guidance-provides-definition-for-orphan-device-offers-alternative-trial-designs/ 2024-07-08T18:17:58+00:00 https://www.agencyiq.com/blog/in-a-new-final-rule-fda-carves-out-a-regulatory-niche-for-medical-gases/ 2024-07-16T17:20:27+00:00 https://www.agencyiq.com/blog/in-marked-shift-the-fda-is-increasingly-tolerant-of-single-pivotal-trials-to-support-approval/ 2024-07-17T15:38:45+00:00 https://www.agencyiq.com/blog/new-ec-report-dives-deep-to-better-understand-shortages-of-critical-medicines/ 2024-07-22T21:54:16+00:00 https://www.agencyiq.com/blog/fda-gives-companies-leeway-to-go-after-misinformation-but-not-free-reign/ 2024-07-22T21:54:16+00:00 https://www.agencyiq.com/blog/facing-headwinds-fda-moves-ahead-on-diagnostics-policy-implementation-but-faces-congressional-legal-and-judicial-questions/ 2024-07-26T16:48:36+00:00 https://www.agencyiq.com/blog/updated-eudamed-roadmap-projects-mandatory-use-of-some-processes-as-early-as-december-2025/ 2024-07-26T16:48:37+00:00 https://www.agencyiq.com/blog/fdas-oncologic-advisors-support-multi-arm-trials-for-multi-phase-regimens/ 2024-07-29T18:55:04+00:00 https://www.agencyiq.com/blog/top-ivdr-notified-body-concern-lack-of-e-u-reference-laboratories-for-high-risk-diagnostics/ 2024-08-02T16:15:47+00:00 https://www.agencyiq.com/blog/fda-finalizes-guidance-on-electronic-submissions-for-otc-products/ 2024-08-02T16:15:47+00:00 https://www.agencyiq.com/blog/digital-health-update-hhs-new-ai-office-fdas-report-on-ai-in-surveillance-and-coming-policy/ 2024-08-09T16:41:30+00:00 https://www.agencyiq.com/blog/eu-executive-consults-on-proposed-update-to-pic-chemical-lists/ 2024-08-09T16:41:31+00:00 https://www.agencyiq.com/blog/fdas-new-metabolic-diseases-committee-gives-hesitant-nod-to-ultra-rare-disease-drug/ 2024-08-16T17:12:25+00:00 https://www.agencyiq.com/blog/heres-how-global-regulators-are-starting-to-think-about-the-use-of-ai-in-drug-development/ 2024-08-21T20:12:16+00:00 https://www.agencyiq.com/blog/emas-psychedelic-workshop-leaves-stakeholders-with-as-many-questions-as-answers/ 2024-08-23T16:18:25+00:00 https://www.agencyiq.com/blog/the-fda-rejected-a-psychedelic-sponsors-bid-for-approval-here-are-six-industry-takeaways/ 2024-08-23T16:18:26+00:00 https://www.agencyiq.com/blog/understanding-the-nuts-and-bolts-of-the-reauthorization-process-for-pdufa-viii/ 2024-08-23T20:31:41+00:00 https://www.agencyiq.com/blog/how-fda-is-already-requiring-companies-to-study-the-safety-and-effectiveness-of-their-approved-drugs-in-diverse-populations/ 2024-08-29T14:05:32+00:00 https://www.agencyiq.com/blog/whats-on-fdas-new-diagnostics-chiefs-mind-transitions-the-ldt-rule-and-cybersecurity/ 2024-08-30T19:39:10+00:00 https://www.agencyiq.com/blog/ema-issues-more-updates-to-prepare-for-clinical-trials-transition/ 2024-08-30T19:39:12+00:00 https://www.agencyiq.com/blog/your-essential-guide-to-the-fda-regulatory-policy-landscape-through-the-end-of-2024/ 2024-09-11T13:47:20+00:00 https://www.agencyiq.com/blog/e-cigarette-lawsuit-may-imperil-fdas-regulation-of-medical-products/ 2024-09-17T20:00:31+00:00 https://www.agencyiq.com/blog/fda-buries-the-lede-on-a-key-benefit-of-multiregional-clinical-trials-more-trustworthy-data/ 2024-09-26T16:40:43+00:00 https://www.agencyiq.com/blog/another-cloud-in-the-sky-fda-and-industry-team-up-to-test-prism-a-new-regulatory-cloud-submissions-platform/ 2024-10-07T12:41:25+00:00 https://www.agencyiq.com/blog/stakeholder-comments-on-fdas-diversity-action-plan-guidance-show-tension-on-scope-and-question-enforceability/ 2024-10-10T18:44:14+00:00 https://www.agencyiq.com/blog/everything-the-fda-does-is-a-violation-of-the-administrative-procedure-act/ 2024-10-22T13:08:54+00:00 https://www.agencyiq.com/blog/what-does-the-advent-of-generative-ai-mean-for-the-fdas-legal-framework/ 2024-10-30T16:07:50+00:00 https://www.agencyiq.com/blog/trump-may-hand-control-of-fda-over-to-rfk-jr-heres-what-that-could-mean-for-fda-and-industry/ 2024-10-31T14:25:35+00:00 https://www.agencyiq.com/blog/the-trump-transition-explainer-everything-you-need-to-know-about-how-the-election-of-donald-trump-could-affect-fda/ 2024-11-18T13:59:10+00:00 https://www.agencyiq.com/blog/the-trump-transition-what-marty-makary-could-mean-for-fda-if-hes-confirmed-as-the-next-commissioner/ 2024-12-02T20:10:36+00:00 https://www.agencyiq.com/blog/the-trump-transition-how-could-trumps-doge-affect-the-fda/ 2024-12-02T20:23:38+00:00 https://www.agencyiq.com/blog/the-trump-transition-how-might-maga-and-mahas-plans-for-fda-clash/ 2024-12-02T20:24:57+00:00 https://www.agencyiq.com/blog/the-trump-transition-the-many-ways-rfk-jr-could-disrupt-fdas-regulation-of-vaccines/ 2024-12-05T13:53:52+00:00 https://www.agencyiq.com/blog/fdas-new-accelerated-approval-guidance-offers-detail-on-withdrawals-process-but-punts-on-confirmatory-studies/ 2024-12-06T21:15:22+00:00 https://www.agencyiq.com/blog/the-trump-transition-the-future-regulatory-philosophy-of-the-fda-is-still-a-mystery/ 2024-12-17T18:03:52+00:00 https://www.agencyiq.com/blog/for-the-first-time-fda-explains-how-it-plans-to-implement-a-critical-process-for-accelerated-approval-reforms/ 2025-01-07T15:22:08+00:00 https://www.agencyiq.com/blog/in-two-new-documents-fda-offers-developers-guidance-on-assessing-sex-based-differences/ 2025-01-16T16:53:04+00:00 https://www.agencyiq.com/blog/what-cder-director-patrizia-cavazzonis-retirement-means-for-fda/ 2025-01-16T16:57:44+00:00 https://www.agencyiq.com/blog/fda-pulls-diversity-action-plan-guidance-other-diversity-programs-after-executive-order/ 2025-01-24T21:29:24+00:00 https://www.agencyiq.com/blog/status-check-whats-going-on-with-fdas-diversity-related-policies/ 2025-01-30T20:02:38+00:00 https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/ 2025-01-30T20:21:49+00:00 https://www.agencyiq.com/blog/fda-updates-guidance-language-forms-to-align-with-trump-executive-order/ 2025-02-04T18:00:00+00:00 https://www.agencyiq.com/blog/trump-reintroduces-revamped-deregulatory-executive-order-one-in-10-out-and-a-bigger-role-for-the-unified-agenda/ 2025-02-04T18:33:44+00:00 https://www.agencyiq.com/blog/the-trump-transition-rfk-has-been-nominated-to-lead-hhs-what-now/ 2025-02-04T18:45:50+00:00 https://www.agencyiq.com/blog/as-government-reform-efforts-converge-significant-fda-staff-cuts-are-likely/ 2025-02-10T19:41:38+00:00 https://www.agencyiq.com/blog/analysis-the-majority-of-novel-drugs-approved-by-fda-rely-on-evidence-from-a-single-pivotal-trial/ 2025-02-10T20:43:49+00:00 https://www.agencyiq.com/blog/critics-of-accelerated-approval-program-offer-early-feedback-on-new-fda-guidance/ 2025-02-11T23:46:17+00:00 https://www.agencyiq.com/blog/impact-of-10-for-1-deregulatory-executive-order-will-extend-beyond-regulations/ 2025-02-11T23:49:12+00:00 https://www.agencyiq.com/blog/analysis-the-scope-and-contents-of-cders-draft-guidance-portfolio/ 2025-02-12T15:28:40+00:00 https://www.agencyiq.com/blog/what-trumps-executive-orders-would-mean-for-the-fda-and-life-sciences-industry/ 2025-02-12T15:37:39+00:00 https://www.agencyiq.com/blog/fda-begins-restoring-some-documents-following-court-order/ 2025-02-13T16:25:29+00:00 https://www.agencyiq.com/blog/what-to-expect-for-makarys-fda-commissioner-confirmation-process/ 2025-02-13T21:56:10+00:00 https://www.agencyiq.com/blog/trump-establishes-maha-commission-with-medicines-and-maybe-user-fees-in-its-crosshairs/ 2025-02-14T23:03:16+00:00 https://www.agencyiq.com/blog/legislators-tee-up-renewed-effort-to-pass-rare-pediatric-drug-bills/ 2025-02-14T23:07:12+00:00 https://www.agencyiq.com/blog/rfk-jr-is-confirmed-as-hhs-secretary-what-now/ 2025-02-14T23:17:05+00:00 https://www.agencyiq.com/blog/under-new-executive-order-fda-to-prep-for-doge-directed-reductions-in-force/ 2025-02-14T23:20:40+00:00 https://www.agencyiq.com/blog/a-guide-to-staff-reductions-fda-has-already-experienced-and-those-coming-soon/ 2025-02-28T21:54:05+00:00 https://www.agencyiq.com/blog/analysis-yes-fdas-workforce-doubled-since-2007-heres-how-and-why-it-did/ 2025-03-20T20:41:43+00:00 https://www.agencyiq.com/blog/following-layoffs-the-future-of-fdas-user-fee-programs-is-in-extreme-jeopardy/ 2025-04-04T00:12:23+00:00 https://www.agencyiq.com/blog/what-we-know-about-makarys-emerging-proposal-for-continuous-trial-reforms/ 2025-11-03T19:31:59+00:00 https://www.agencyiq.com/blog/in-a-major-shift-fda-unveils-crackdown-on-dtc-drug-advertising-with-a-plan-to-make-drugs-ads-infeasible/ 2025-11-03T19:36:11+00:00 https://www.agencyiq.com/blog/sluggish-biomarker-program-offers-fda-opportunity-for-reform/ 2025-11-06T20:54:15+00:00 https://www.agencyiq.com/blog/policy-and-promises-tracking-makarys-first-year-running-the-fda/ 2026-04-02T23:01:53+00:00 https://www.agencyiq.com/blog/are-eu-substitution-centers-in-the-cards-for-quicker-substitution-of-toxic-chemicals/ 2026-08-12T16:27:29+00:00 https://www.agencyiq.com/blog/echa-issues-guidelines-for-enforcing-mixture-classification-based-on-bridging-principles/ 2026-08-12T16:27:51+00:00 https://www.agencyiq.com/blog/epa-announces-string-of-deregulatory-actions-affecting-chemicals-related-rules/ 2026-08-12T16:28:18+00:00 https://www.agencyiq.com/blog/commission-proposes-exemptions-to-uv-328-ban-under-pops-regulation/ 2026-08-12T16:29:18+00:00 https://www.agencyiq.com/blog/commission-unveils-details-on-plan-for-phasing-out-animal-testing-for-chemicals-safety/ 2026-08-12T16:29:39+00:00 https://www.agencyiq.com/blog/epa-grants-petition-on-pfas-in-fluorinated-containers/ 2026-08-12T16:30:02+00:00 https://www.agencyiq.com/blog/epa-publishes-interagency-framework-on-antifungal-and-antibiotic-resistance-from-pesticides/ 2026-08-12T16:30:17+00:00 https://www.agencyiq.com/blog/why-comprehensive-state-level-bans-on-pfas-in-products-are-faltering/ 2026-08-12T16:30:38+00:00 https://www.agencyiq.com/blog/echa-committees-conclude-evaluation-of-several-pfas-uses-subject-to-proposed-restrictions/ 2026-08-12T16:30:53+00:00 https://www.agencyiq.com/blog/what-is-regulatory-intelligence/ 2026-08-12T19:35:08+00:00 https://www.agencyiq.com/blog/swiss-regulators-align-with-eu-on-chemicals-biocides/ 2026-08-12T20:08:36+00:00 https://www.agencyiq.com/blog/european-commission-issues-eu-wide-rules-on-pesticide-ingredients/ 2026-08-12T20:08:59+00:00 https://www.agencyiq.com/blog/commission-issues-methodology-to-measure-microplastics-in-drinking-water/ 2026-08-12T20:09:19+00:00 https://www.agencyiq.com/blog/epas-toxicological-review-of-pfna-gets-mixed-reviews-from-government-industry/ 2026-08-12T20:09:35+00:00 https://www.agencyiq.com/blog/france-reintroduces-pesticide-plan-this-time-with-eu-indicator/ 2026-08-12T20:10:00+00:00 https://www.agencyiq.com/blog/what-we-expect-eu-chemical-regulators-to-do-in-may-2024/ 2026-08-12T20:10:56+00:00 https://www.agencyiq.com/blog/efsas-novel-bpa-assessment-approach-defended-amid-national-regulatory-dissent/ 2026-08-12T20:11:18+00:00 https://www.agencyiq.com/blog/hse-elicits-input-to-support-restriction-proposal-on-pfas-in-firefighting-foams/ 2026-08-12T20:11:36+00:00 https://www.agencyiq.com/blog/french-pfas-ban-exempts-cookware-clears-national-assembly/ 2026-08-12T20:11:57+00:00 https://www.agencyiq.com/blog/3m-pfas-settlement-gains-final-court-approval/ 2026-08-12T20:12:16+00:00 https://www.agencyiq.com/blog/echa-flags-28-substances-for-evaluation-over-next-three-years/ 2026-08-12T20:12:32+00:00 https://www.agencyiq.com/blog/echa-unveils-6-month-plan-to-evaluate-universal-pfas-restriction-proposal/ 2026-08-12T20:12:46+00:00 https://www.agencyiq.com/blog/at-conference-echa-calls-for-regulatory-coherence-collaboration-to-achieve-green-and-digital-transition/ 2026-08-12T20:13:06+00:00 https://www.agencyiq.com/blog/what-we-expect-eu-regulators-to-do-in-march-2024/ 2026-08-12T20:13:28+00:00 https://www.agencyiq.com/blog/epa-poised-to-strengthen-chemical-facility-risk-management-program-regulations/ 2026-08-12T20:14:16+00:00 https://www.agencyiq.com/blog/european-commission-unveils-proposed-ban-on-bisphenol-a-in-food-packaging/ 2026-08-12T20:14:33+00:00 https://www.agencyiq.com/blog/epa-issues-guidance-on-absence-of-ingredient-label-claims-for-pesticides/ 2026-08-12T20:14:50+00:00 https://www.agencyiq.com/blog/what-we-expect-eu-regulators-to-do-in-february-2024/ 2026-08-12T20:15:13+00:00 https://www.agencyiq.com/blog/epa-scientific-integrity-plan-long-on-policy-short-on-enforcement/ 2026-08-12T20:15:39+00:00 https://www.agencyiq.com/blog/epa-proposes-meat-and-poultry-effluent-standards/ 2026-08-12T20:16:09+00:00 https://www.agencyiq.com/blog/commission-unveils-one-substance-one-assessment-reform-package/ 2026-08-12T20:16:35+00:00 https://www.agencyiq.com/blog/epa-issues-new-chemicals-decision-framework-to-assess-eye-irritation-and-corrosion/ 2026-08-12T20:17:10+00:00 https://www.agencyiq.com/blog/what-we-expect-eu-regulators-to-do-in-january-2024/ 2026-08-12T20:17:32+00:00 https://www.agencyiq.com/blog/epa-orders-manufacturer-to-stop-producing-pfas-and-manufacturer-petitions-court/ 2026-08-12T20:17:50+00:00 https://www.agencyiq.com/blog/echa-head-unveils-agency-priorities-promises-unbiased-assessment-of-pfas-restriction/ 2026-08-12T20:18:15+00:00 https://www.agencyiq.com/blog/what-we-expect-eu-regulators-to-do-in-december-2023/ 2026-08-12T20:18:51+00:00 https://www.agencyiq.com/blog/california-adds-three-substances-to-proposition-65-list/ 2026-08-12T20:19:25+00:00 https://www.agencyiq.com/blog/epa-publishes-draft-meaningful-involvement-policy/ 2026-08-12T20:19:54+00:00 https://www.agencyiq.com/blog/wisconsin-dnr-finds-pfas-in-71-of-shallow-groundwater-samples/ 2026-08-12T20:20:26+00:00 https://www.agencyiq.com/blog/schakowsky-introduces-bill-to-ban-pfas-other-chemicals-as-food-contact-substances/ 2026-08-12T20:30:41+00:00 https://www.agencyiq.com/blog/what-we-expect-eu-regulators-to-do-in-november-2023/ 2026-08-12T20:30:58+00:00 https://www.agencyiq.com/blog/supreme-court-agrees-to-hear-additional-case-which-could-erode-or-erase-deference-to-agencies-like-fda-and-epa/ 2026-08-12T20:32:46+00:00 https://www.agencyiq.com/blog/epa-issues-proposed-and-final-rules-to-further-cut-down-hfc-use/ 2026-08-12T20:33:13+00:00 https://www.agencyiq.com/blog/the-epa-has-a-new-enforceable-definition-for-pfas-what-does-it-actually-cover/ 2026-08-12T20:33:28+00:00 https://www.agencyiq.com/blog/e-u-chemical-developments-were-expecting-in-october-2023/ 2026-08-12T20:33:43+00:00 https://www.agencyiq.com/blog/france-finds-unclear-disinfectant-labeling-to-blame-for-chemical-burns-in-children/ 2026-08-12T20:33:57+00:00 https://www.agencyiq.com/blog/california-set-to-ban-an-additional-26-chemicals-from-cosmetics/ 2026-08-12T20:47:26+00:00 https://www.agencyiq.com/blog/epa-updates-human-health-drinking-water-assessments-for-acephate/ 2026-08-12T20:47:50+00:00 https://www.agencyiq.com/blog/eus-pic-regulation-adds-35-new-entries/ 2026-08-12T20:48:12+00:00 https://www.agencyiq.com/blog/epa-scraps-ozone-plans/ 2026-08-12T20:48:31+00:00 https://www.agencyiq.com/blog/epa-labs-lack-proper-inspections-watchdog-says/ 2026-08-12T20:48:45+00:00 https://www.agencyiq.com/blog/glyphosate-an-eu-regulatory-roundup/ 2026-08-12T20:49:03+00:00 https://www.agencyiq.com/blog/epa-oig-chides-epa-for-consistency-and-transparency-in-decisions/ 2026-08-12T20:49:17+00:00 https://www.agencyiq.com/blog/epa-proposes-bans-and-restrictions-on-the-use-of-carbon-tetrachloride/ 2026-08-12T20:49:32+00:00 https://www.agencyiq.com/blog/dust-in-the-wind-new-epa-regulations-to-sweep-up-lead-levels-in-many-structures/ 2026-08-12T20:49:53+00:00 https://www.agencyiq.com/blog/new-epa-pfas-framework-expects-most-pfas-to-be-pbts/ 2026-08-12T20:50:25+00:00 https://www.agencyiq.com/blog/updated-14-dioxane-risk-evaluation-reviews-new-exposure-pathways/ 2026-08-12T20:50:45+00:00 https://www.agencyiq.com/blog/usgs-estimates-at-least-45-of-u-s-tap-water-contains-pfas/ 2026-08-12T20:51:13+00:00 https://www.agencyiq.com/blog/epa-proposes-ban-on-the-consumer-use-and-most-industrial-and-commercial-uses-of-perchloroethylene/ 2026-08-12T20:52:57+00:00 https://www.agencyiq.com/blog/epa-flips-on-trump-era-plan-to-exempt-pyrolysis-from-caa-regs/ 2026-08-12T20:53:16+00:00 https://www.agencyiq.com/blog/epa-lab-contradicts-previous-study-on-pfas-in-pesticide-products/ 2026-08-12T20:53:30+00:00 https://www.agencyiq.com/blog/epa-proposes-amendments-to-tsca-new-chemicals-and-to-remove-exemptions-for-pfas-and-pbts/ 2026-08-12T20:53:45+00:00 https://www.agencyiq.com/blog/washington-state-requests-comment-on-draft-phthalate-plan/ 2026-08-12T20:54:01+00:00 https://www.agencyiq.com/blog/eu-restricts-lead-in-pvc-products/ 2026-08-12T20:54:15+00:00 https://www.agencyiq.com/blog/eeb-and-eea-call-out-commission-for-regulatory-shortcomings/ 2026-08-12T20:54:28+00:00 https://www.agencyiq.com/blog/reach-revision-status-report-increased-information-requirements/ 2026-08-12T20:54:40+00:00 https://www.agencyiq.com/blog/ej-for-nj-new-environmental-justice-rules-go-into-effect/ 2026-08-12T20:54:56+00:00 https://www.agencyiq.com/blog/epa-floats-listing-seven-additional-pfas-under-cercla/ 2026-08-12T20:55:10+00:00 https://www.agencyiq.com/blog/eu-rolls-out-new-hazard-classes-in-the-clp-regulation/ 2026-08-12T20:55:27+00:00 https://www.agencyiq.com/blog/epa-presents-technical-details-of-proposed-pfas-drinking-water-rules/ 2026-08-12T20:55:39+00:00 https://www.agencyiq.com/blog/eu-commission-to-add-dozens-of-chemicals-to-pic-regulation/ 2026-08-12T20:56:00+00:00 https://www.agencyiq.com/blog/epa-proposes-national-primary-drinking-water-regulation-for-six-pfas/ 2026-08-12T20:56:17+00:00 https://www.agencyiq.com/blog/eu-commission-approves-nearly-100-chemical-safety-test-methods-streamlines-procedure-for-future-additions/ 2026-08-12T20:56:31+00:00 https://www.agencyiq.com/blog/doj-sues-denka-dupont-over-louisiana-plant-emissions/ 2026-08-12T20:57:20+00:00 https://www.agencyiq.com/blog/2021-ban-on-long-chain-pfas-subgroup-to-take-effect/ 2026-08-12T20:57:57+00:00 https://www.agencyiq.com/blog/epa-publishes-protocol-for-iris-ethylbenzene-assessment/ 2026-08-12T20:58:12+00:00 https://www.agencyiq.com/blog/echa-publishes-2023-work-program/ 2026-08-12T20:58:41+00:00 https://www.agencyiq.com/blog/epas-sab-poised-to-issue-draft-report-supporting-epa-methane-rules-for-oil-and-gas/ 2026-08-12T20:58:59+00:00 https://www.agencyiq.com/blog/canada-floats-reduced-animal-testing-for-new-substance-notification-regulations-for-chemicals-and-polymers/ 2026-08-12T20:59:18+00:00 https://www.agencyiq.com/blog/echa-finds-no-need-to-take-further-risk-management-action-for-acrylate-and-methacrylate-amines-group/ 2026-08-12T20:59:35+00:00 https://www.agencyiq.com/blog/regulatory-highlights-from-the-final-week-of-2022/ 2026-08-12T20:59:55+00:00 https://www.agencyiq.com/blog/eu-commission-reviews-exemptions-for-restriction-on-leaded-automobile-manufacturing-materials/ 2026-08-12T21:00:24+00:00 https://www.agencyiq.com/blog/epa-revises-n-methylpyrrolidone-tsca-risk-determination/ 2026-08-12T21:02:16+00:00 https://www.agencyiq.com/blog/epa-issues-pfas-discharge-permit-guidance-to-epa-regions/ 2026-08-12T21:02:35+00:00 https://www.agencyiq.com/blog/oehha-publishes-cic-agenda-for-bpa-meeting/ 2026-08-12T21:02:48+00:00 https://www.agencyiq.com/blog/department-of-energy-releases-initial-report-on-pfas-at-doe-sites/ 2026-08-12T21:03:15+00:00 https://www.agencyiq.com/blog/industry-weighs-in-on-proposal-to-restrict-dipolar-aprotic-solvents-dmac-and-nep/ 2026-08-12T21:03:30+00:00 https://www.agencyiq.com/blog/epa-finalizes-contaminant-candidate-list-5-includes-multiple-pfas-structures/ 2026-08-12T21:03:45+00:00 https://www.agencyiq.com/blog/chemicals-strategy-sidelined-after-commission-reprioritizes-actions-amid-inflation-and-energy-crises/ 2026-08-12T21:04:00+00:00 https://www.agencyiq.com/blog/eu-lawmakers-call-on-commission-to-withdraw-approval-of-active-substances/ 2026-08-12T21:04:24+00:00 https://www.agencyiq.com/blog/center-for-food-safety-sues-epa-over-unanswered-petition-on-inert-ingredients-in-pesticides/ 2026-08-12T21:04:38+00:00 https://www.agencyiq.com/blog/more-litigation-of-ethylene-oxide-likely-coming-after-sterigenics-trial/ 2026-08-12T21:04:57+00:00 https://www.agencyiq.com/blog/epas-office-of-land-and-emergency-management-publishes-new-environmental-justice-action-plan/ 2026-08-12T21:05:32+00:00 https://www.agencyiq.com/blog/epa-withdraws-glyphosate-interim-registration-review-decision/ 2026-08-12T21:05:51+00:00 https://www.agencyiq.com/blog/sixth-circuit-grants-review-of-pfas-class-action-lawsuit/ 2026-08-12T21:06:39+00:00 https://www.agencyiq.com/blog/epa-and-ge-agree-on-pcb-research-plan-for-hudson-valley/ 2026-08-12T21:06:52+00:00 https://www.agencyiq.com/blog/west-virginia-v-epa-the-major-questions-doctrine-has-the-potential-to-cause-major-problems-for-regulators/ 2026-08-12T21:07:17+00:00 https://www.agencyiq.com/blog/d-c-circuit-transfers-sierra-club-pfas-case-to-fifth-circuit/ 2026-08-12T21:07:32+00:00 https://www.agencyiq.com/blog/epa-discontinues-use-of-exposure-modeling-thresholds-in-review-of-new-chemicals/ 2026-08-12T21:09:22+00:00 https://www.agencyiq.com/blog/epa-reaches-out-to-communities-exposed-to-ethylene-oxide-emissions-from-commercial-sterilizers/ 2026-08-12T21:09:55+00:00 https://www.agencyiq.com/blog/finding-your-way-around-echas-chemical-universe/ 2026-08-12T21:10:31+00:00 https://www.agencyiq.com/blog/epa-holds-meeting-to-discuss-delays-in-new-chemicals-determinations/ 2026-08-12T21:10:46+00:00 https://www.agencyiq.com/blog/congress-to-consider-bill-to-coordinate-the-study-and-mitigation-of-pfas/ 2026-08-12T21:10:58+00:00 https://www.agencyiq.com/blog/senate-environment-and-public-works-committee-holds-hearing-on-three-monitoring-bills/ 2026-08-12T21:11:14+00:00 https://www.agencyiq.com/blog/commission-proposes-halving-pesticide-use-in-eu-by-2030/ 2026-08-12T21:11:26+00:00